Compare Noble Corporation plc (NE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Novo Nordisk A/S — how do they compare? Noble Corporation plc trades at $44.35 (market cap $7.10B), while Novo Nordisk A/S trades at $46.11 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 29.3× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.5%). Which is the better fit depends on your goals.
| NE | NVO | |
|---|---|---|
Market Cap | $7.10B | $207.85B |
Sector | Technology | Health |
52-Week High | $54.37 | $63.98 |
52-Week Low | $26.61 | $35.29 |
Enterprise Value | $8.53B | $222.55B |
Dividend Yield | 4.5% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $44.48, up 2.14% today, with a bullish technical signal driven by moving averages. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss, while revenue and net income have declined year-over-year. Recent news highlights multiple law firm investigations into the company, adding uncertainty. The consensus price target is $46.00, slightly above the current price, with analysts divided between Buy (31%) and Hold (43%) ratings.
The outlook is cautious due to earnings volatility and legal scrutiny, though positive cash flow and a solid backlog of $6.8 billion provide some stability. Key risks include operational suspensions and investor litigation, while potential upside hinges on execution improvements and contract wins. The stock's valuation appears stretched with a P/E of 47.32, demanding strong future growth to justify current levels.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
